Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BL-B01D1 with or without a PD-1 antibody in high-risk locoregionally advanced nasopharyngeal carcinoma
CTR20263357Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan, PD-1 Monoclonal Antibody in nasopharyngeal carcinoma (NPC), sponsored by Biokin Pharmaceutical. Started Aug 2026; status: active.
02
Drugs
izalontamab brengitecanPD-1 Monoclonal Antibody
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20263357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263357.